TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02146469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 doses with an 3 months interval
Description: varicella vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A second dose with an 1 year interval
Description: varicella vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A second dose with an 3 year interval
Description: varicella vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A second dose with an 5 year interval
Description: varicella vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 dose Varicella vaccine and 1 dose MMR given at the same time
Description: varicella vaccine and MMR

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 1 dose MMR
Description: MMR
Study: NCT02282709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: 60 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asunaprevir
Description: 100 mg BID
Study: NCT02808403

Intervention type: OTHER
Intervention: No intervention
Description: No intervention; observation of routine medical care
Study: NCT01420497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-articular infiltration
Description: intra articular infiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural infiltration
Description: epidural infiltration
Study: NCT03836105

Intervention type: DRUG
Intervention: cemiplimab
Description: No investigational agents will be provided to enrolled patients by the sponsor as part of this study. Patients will have recently initiated or be planning to initiate treatment with commercially available cemiplimab for advanced CSCC or advanced BCC in a real-world setting according to respective label indications. In addition to cemiplimab, patients may receive other therapies as deemed necessary by their physicians for the treatment of CSCC or BCC or comorbid conditions.

Intervention type: DRUG
Intervention: cemiplimab
Description: No investigational agents will be provided to enrolled patients by the sponsor as part of this study. Patients will have recently initiated or be planning to initiate treatment with commercially available cemiplimab for advanced CSCC or advanced BCC in a real-world setting according to respective label indications. In addition to cemiplimab, patients may receive other therapies as deemed necessary by their physicians for the treatment of CSCC or BCC or comorbid conditions.
Study: NCT02180815

Intervention type: DEVICE
Intervention: ReVENT Sleep Apnea System
Study: NCT03169933

Intervention type: RADIATION
Group type: OTHER
Intervention: Combined, intensified and modulated adjuvant radiotherapy
Study: NCT02411006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Remind people to take their medicine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Remind people to take their medicine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Remind people to take their medicine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Remind people to take their medicine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Remind people to take their medicine
Study: NCT03730818

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land-based Exercise Group
Description: The intervention will consist of a land-based exercise protocol
Study: NCT04373512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Culturelle 10 Billion CFU Capsule (2 doses)
Description: For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 2 LGG capsules and will repeat this process the following night (Low dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Culturelle 10 Billion CFU Capsule (4 doses)
Description: For the LGG instillation, participants will be instructed to mix the contents of 1 LGG capsule into saline. After mixing, participants will draw up the liquid LGG mixture into a syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 4 LGG capsules and will repeat this process twice daily for a total of four doses (High dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining capsules
Study: NCT03878979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 480mg and surgical resection
Description: One dose of Nivolumab 480mg given four weeks prior to surgical resection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 480mg and surgical resection
Description: One dose of Nivolumab 480mg given four weeks prior to surgical resection.
Study: NCT01229384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure nebulization
Description: Using a device approved in pediatrics to deliver nebulized treatments of albuterol and racemic epinephrine with positive pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard passive nebulization of respiratory medications
Description: Patients will receive standard passively inhaled nebulized albuterol and racemic epinephrine.
Study: NCT06274086

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-session catheter-directed sclerotherapy
Description: After receiving the first session of catheter-directed sclerotherapy, each patient carries the catheter overnight and is closely monitored in the patient ward. Then, the patient receives the second session the next day. The catheter is removed after the second session.~The procedure was performed under intravenous sedoanalgesia using a combination of 25 mg pethidine hydrochloride and 50 mg fentanyl. Devices used during the procedure included:~* An 18-gauge, 20-cm Chiba biopsy needle (Cook, Bloomington, IN, USA);~* A 0.035-inch hydrophilic guidewire (Terumo, Tokyo, Japan);~* A 7- or 8.5-F pigtail catheter (Dawson-Mueller Drainage Catheter; Cook).
Study: NCT00110552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvia officinalis (sage)
Description: oral dosage
Study: NCT01693211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond Laser (VICTUS™ Femtosecond Laser Platform)
Description: Capsulotomy and pre-fragmentation of the nucleus are performed by the femtosecond laser.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual (CCC technique with Utrata forceps)
Description: Capsulorhexis and pre-fragmentation are performed manually.
Study: NCT00249769

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Japanese encephalitis vaccine SA 14-14-2 (LJEV)
Description: Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) is lyophilized powder that looks like a milky-white crisp cake. After reconstitution, it turns into a transparent orange red liquid. Its container is a vial. It is stored and transported between 2°C to 8°C and protected from light. Each single human dose is 0.5 ml containing not less than 5.4 log particle flux unit (PFU) of live Japanese Encephalitis (JE) virus. The 0.5ml injection is delivered subcutaneously via auto-disable syringe. Lot number 200411129-3 manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China.
Study: NCT01145001

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Description: incentives given for abstinence based on urine analysis

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Contingency Management
Description: incentives given for abstinence based on urine analysis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Transdermal Patch
Description: 14mg ir 21mg doses based on weight and #cigs/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Transdermal Patch
Description: 14mg ir 21mg doses based on weight and #cigs/day
Study: NCT00713778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian cystectomy
Description: Laparoscopic ovarian cystectomy using bipolar

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian cystectomy
Description: Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
Study: NCT02411006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anonymity
Description: Keep patient predictions and commitment anonymous

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anonymity
Description: Keep patient predictions and commitment anonymous

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identification
Description: Ask patients to report their predictions and commitments

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identification
Description: Ask patients to report their predictions and commitments
Study: NCT02061163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Ultrasound
Description: Subjects with Crohn's disease will undergo contrast enhanced ultrasound imaging with shear wave elastography. Both CEUS and shear wave elastography will be performed using FDA approved ultrasound machines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optison
Description: Optison is a microbubble contrast agent (dye) that will be injected during the CEUS imaging. Optison is FDA-approved for use in heart ultrasounds but not approved for use in bowel ultrasounds. Its use in this study is considered investigational (off-label).
Study: NCT00713778

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian cystectomy
Description: Laparotomic ovarian cystectomy using suture
Study: NCT00114764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Filgrastim given daily after induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Pegfilgrastim given once after induction chemotherapy
Study: NCT02259764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUC 7483 CL - single rising dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized high fat meal
Study: NCT00408772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study: NCT02619955

Intervention type: OTHER
Intervention: samples with DNA
Study: NCT01198431

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep duration
Description: Duration of sleep per night
Study: NCT00408772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT01198431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep duration
Description: Duration of sleep per night
Study: NCT00408772

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Study: NCT00405275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: etanercept, subcutaneous injection
Study: NCT05845515

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic orchiopexy
Description: laparoscopic or open orchiopexy and comparison between the two groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic orchiopexy
Description: laparoscopic or open orchiopexy and comparison between the two groups
Study: NCT03947346

Intervention type: OTHER
Intervention: Urine sample
Description: The urine collected from the first morning void will be used to assess urine creatinine and microalbumin. The fresh urine specimen will be analyzed for novel urinary biomarkers of (urinary NGAL, TGF-β1, IL-18 and KIM-1). Serum BUN, creatinine, and cystatin-C will be assessed using serum samples drawn for routine clinical care.
Study: NCT04337944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Boston keratoprosthesis type 1 and anterior hyaloid membrane peeling assisted by endoscopy
Description: Patients will receive at the same time a Boston keratoprosthesis type 1 (KPro) with a pars plana vitrectomy (PPV) with anterior hyaloid membrane peeling assisted by endoscopy.
Study: NCT02157116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT04667598

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modified Wenxin Decoction
Description: Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Wenxin Decoction
Description: Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.
Study: NCT00005947

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sipuleucel-T
Description: Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Approximately one-third of the autologous quiescent antigen presenting cells (APCs) prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
Study: NCT01545791

Intervention type: DRUG
Intervention: insulin detemir
Description: Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
Study: NCT00741897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine: One 30 mg Tablet once daily for two weeks
Study: NCT00810277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks for 24 weeks
Study: NCT00869791

Intervention type: DRUG
Group type: OTHER
Intervention: IPX066
Description: experimental drug product: extended-release carbidopa-levodopa capsules

Intervention type: DRUG
Group type: OTHER
Intervention: IPX066
Description: experimental drug product: extended-release carbidopa-levodopa capsules

Intervention type: DRUG
Group type: OTHER
Intervention: IR CD-LD
Description: active comparator: immediate-release carbidopa-levodopa capsules

Intervention type: DRUG
Group type: OTHER
Intervention: IR CD-LD
Description: active comparator: immediate-release carbidopa-levodopa capsules
Study: NCT02485249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate Ophthalmic
Description: Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
Study: NCT00143494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: measurement of abdominal pressure
Description: measurement of abdominal pressure with different volume and saline temperature
Study: NCT04874883

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Simbyotic
Description: 6 grams of the symbiotic will be administered twice a day

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: 6 grams of the maltodextrin will be administered twice a day
Study: NCT01659996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide diphtheria toxoid conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate
Description: 0.5 mL, Intramuscular
Study: NCT02137018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPL fixation by BP
Description: A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by BP patch. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable stitches on the cutaneous layer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPL fixation by BP
Description: A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by BP patch. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable stitches on the cutaneous layer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PPL mesh
Description: A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by absorbable stichtes. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable suture on the cutaneous layer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PPL mesh
Description: A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by absorbable stichtes. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable suture on the cutaneous layer.
Study: NCT02094378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: 84 mg esketamine administered intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esketamine
Description: 84 mg esketamine administered intranasally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intranasally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered intranasally
Study: NCT01158820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine load
Description: Dexmedetomidine 1 µg/kg prior to bronchoscopy
Study: NCT02157116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study: NCT00744913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm patches
Description: Women in this group will receive standard counselling and NRT (Nicoderm patches) starting with a dose of 14 mg/day that can be increased to 21 mg/day based on response (smoking cessation) and potential side effects

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counselling
Description: Women in this arm of the study will receive standard counseling only.
Study: NCT01862016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: APRV
Description: Pressure ventilation mode allowing early spontaneous breathing

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: arterial blood gas measurement each morning

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: arterial blood gas measurement each morning
Study: NCT01650896

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Geriatric assessment review
Description: Adjust medications, treat precipitants of delirium, one-on-one supervision of agitated violent patients
Study: NCT04105816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 892.1550 Ultrasonic pulsed doppler imaging system
Description: Use of the ultrasound to measure quadriceps volume

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 892.1550 Ultrasonic pulsed doppler imaging system
Description: Use of the ultrasound to measure quadriceps volume

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thigh circumference measurement
Description: Tape measure used to measure thigh circumference of all participating patients in the study at the same visit in which they receive ultrasound measurements of thigh muscles.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Thigh circumference measurement
Description: Tape measure used to measure thigh circumference of all participating patients in the study at the same visit in which they receive ultrasound measurements of thigh muscles.
Study: NCT00795184

Intervention type: DEVICE
Group type: OTHER
Intervention: Imaging procedures (NBI)
Description: Imaging procedures (pCLE) and (NBI) - All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.~Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.~Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.~After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites.

Intervention type: DEVICE
Group type: OTHER
Intervention: Imaging procedures (NBI)
Description: Imaging procedures (pCLE) and (NBI) - All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.~Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.~Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.~After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites.

Intervention type: DEVICE
Group type: OTHER
Intervention: HDWLE